Volume | 406,153 |
|
|||||
News | - | ||||||
Day High | 2.83 | Low High |
|||||
Day Low | 2.64 |
Company Name | Stock Ticker Symbol | Market | Type |
---|---|---|---|
Regulus Therapeutics Inc | RGLS | NASDAQ | Common Stock |
Open Price | Low Price | High Price | Close Price | Prev Close |
---|---|---|---|---|
2.83 | 2.64 | 2.83 | 2.65 | 2.69 |
Trades | Volume | VWAP | Dollar Volume | Avg Volume | 52 Week Range |
---|---|---|---|---|---|
4,484 | 406,153 | $ 2.72 | $ 1,103,613 | - | 1.08 - 3.78 |
Last Trade Time | Type | Quantity | Stock Price | Currency |
---|---|---|---|---|
19:14:10 | 1 | $ 2.62 | USD |
Regulus Therapeutics Inc Financials
Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
---|---|---|---|---|---|---|
53.39M | 20.22M | - | 0 | -30.04M | -1.49 | - |
Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
---|---|---|---|---|---|
- | - | - | - |
Regulus Therapeutics News
Loading Messages....
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical RGLS Price Data
Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
---|---|---|---|---|---|---|---|
1 Week | 2.30 | 2.90 | 2.21 | 2.54 | 385,319 | 0.32 | 13.91% |
1 Month | 2.52 | 2.90 | 2.09 | 2.54 | 283,612 | 0.10 | 3.97% |
3 Months | 1.42 | 3.78 | 1.32 | 2.38 | 3,357,950 | 1.20 | 84.51% |
6 Months | 1.37 | 3.78 | 1.08 | 2.37 | 1,584,631 | 1.25 | 91.24% |
1 Year | 1.29 | 3.78 | 1.08 | 2.35 | 795,918 | 1.33 | 103.10% |
3 Years | 1.36 | 3.78 | 0.1576 | 1.10 | 1,123,465 | 1.26 | 92.65% |
5 Years | 1.08 | 3.78 | 0.1576 | 1.17 | 1,188,077 | 1.54 | 142.59% |
Regulus Therapeutics Description
Regulus Therapeutics Inc is a biotechnology company focused on the development of microRNA therapies. MicroRNA therapies target diseases such as cancer, metabolic diseases, fibrosis, and inflammatory diseases. MicroRNA is a noncoding ribonucleic acid that regulates most genes in the genome. The company partnered with Sanofi to create a compound targeting orphan diseases and with AstraZeneca to cure Type 2 Diabetes/prediabetes. |